Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix in the News

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Form 8937
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Tonix in the News
  • Tonix Sponsored News
  • IR Events
  • Email Alerts
  • Op-Eds
ASM.org | Nov 13, 2024

Potential Single-Dose Smallpox and Mpox Vaccine Advances

mSphere | Nov 13, 2024

Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both in vitro and in vivo models

Fierce Pharma | Sep 19, 2024

New migraine drugs less effective than previous generation of triptan meds: BMJ study

Chemical & Engineering News | Sep 18, 2024

R&D for long COVID is collapsing

The National News | Sep 1, 2024

Big Pharma treating mpox as African problem puts global population at risk

DailyMail | Aug 3, 2024

New 'lethal' mpox variant is spreading 'unchecked', posing 'severe' risk to hundreds of thousands with one in ten children dying from disease after suffering fever, rashes and pus-filled blisters, experts warn

PharmaVoice | Aug 28, 2023

Why pharma isn’t done tackling migraines

STAT | Apr 20, 2023

The NIH has poured $1 billion into long Covid research — with little to show for it

BioSpace | Apr 13, 2023

Treatment Approach to Depression Sees Paradigm Shift

Inside Health Policy | Sep 29, 2022

Executive Order Could Lead To Big Subsidies For Domestic Biopharmaceutical Manufacturing

Nature Biotechnology | Sep 9, 2022

Monkeypox response relies on three vaccine suppliers

Endpoints News | Aug 24, 2022

'Nothing escapes our scientists': A handful of biotechs gear up work on monkeypox

The Frederick News-Post | Aug 18, 2022

Tonix Pharmaceuticals develops monkeypox vaccine for future by looking at past

BioProcess International | Aug 16, 2022

Tonix looks to live virus vaccines to prevent the spread of monkeypox

New Bedford Guide | Jun 22, 2022

Tonix Pharmaceuticals facility officially opens in the New Bedford Business Park

BioCentury | Jun 14, 2022

Poxvirus agents, by the mechanisms

The New York Times | Jun 3, 2022

21 Americans Infected With Monkeypox, C.D.C. Reports

Bioprocess Online | May 31, 2022

What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D. (Podcast)

Bloomberg | May 2, 2022

Balance of Power: Omicron Subvariant Raises Concerns (Podcast)

FiercePharma | Mar 8, 2022

Mass General plans study of nasally delivered binge eating disorder drug

rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.